All In Biotech

Drug Trial Radar · NCT00448864

Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement

KALAHARI-1: Kallikrein Antagonist (DX-88 [Ecallantide]) Effect on Blood Loss Associated With Heart Surgery Requiring Institution of Bypass

Last checked: Nov 20, 2026Latest source record: Jun 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

75

Actual

Start

May 1, 2007

Primary completion

Jul 1, 2008

Study completion Aug 1, 2008

Sponsor

Sponsor type
Industry
First posted
Mar 19, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to assess the efficacy and safety of 2 dose levels of ecallantide versus placebo in reducing blood loss following cardiopulmonary bypass (CPB), as measured by chest tube drainage during the first 12 hours postoperatively or until the chest tube was removed, whichever came first, in patients undergoing primary coronary artery bypass grafting (CABG), single valve repair, or single valve replacement. The secondary objective was to compare the efficacy of all ecallantide-treated participants (pooled high and low-doses) to placebo and to compare the high-dose to the low-dose ecallantide group. Other secondary objectives were to evaluate pharmacokinetics and antibody formation.

Conditions

  • Blood Loss, Surgical

Interventions

  • EcallantideDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative Chest Tube Drainage During the First 12 Hours PostoperativelyTime frame: Up to 12 hours post admission to intensive care unit (ICU)

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • St. Vincent's Hospital

    Birmingham, Alabama

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • University of Colorado

    Aurora, Colorado

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Caritas St. Elizabeth's Medical Center

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • SUNY Upstate Medical University

    Syracuse, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Gaston Memorial Hospital

    Gastonia, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • The Methodist Hospital

    Houston, Texas

  • Texas Heart Institute

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.